By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Theravance, Inc. 

901 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-808-6000 Fax: 650-827-8690



Company News
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Begin Pivotal Phase 3 Trial For Triple Combination Treatment 7/16/2014 7:42:21 AM
Theravance, Inc. (THRX) Release: Anoro® Ellipta® (Umeclidinium/Vilanterol) Gains Approval In Japan For The Treatment Of COPD 7/7/2014 12:28:54 PM
Theravance, Inc. (THRX) Appoints Theodore J. Witek, Jr. As Senior Vice President, Corporate Partnerships, Clinical And Medical Affairs 7/3/2014 9:21:35 AM
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Submission To US Regulatory Authorities For Fluticasone Furoate/Vilanterol In Asthma 6/30/2014 11:10:57 AM
Theravance, Inc. (THRX) Appoints George B. Abercrombie As Senior Vice President, Corporate Partnerships, Commercial 6/13/2014 8:39:17 AM
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Positive Data From Two Studies Evaluating The Efficacy And Safety Of Incruse® Ellipta® When Added To Relvar®/Breo® Ellipta(®) In Patients With COPD 6/12/2014 10:14:20 AM
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Put Out Positive Update On Two Phase 3 Ellipta COPD Studies 6/11/2014 5:58:52 AM
Theravance, Inc. (THRX) And Theravance Biopharma, Inc. Announce Completion Of Separation Of Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations 6/3/2014 9:33:25 AM
Theravance, Inc. (THRX) To Present At The Jefferies and Co. 2014 Healthcare Conference 5/22/2014 8:52:51 AM
Theravance, Inc. (THRX) Announces Effectiveness Of Form 10 Registration Statement Of Theravance Biopharma, Inc. 5/16/2014 9:50:47 AM